Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis

JC van Denderen, IM Visman… - The Journal of …, 2014 - jrheum.org
Objective. To investigate whether use of adalimumab decreases the frequency of attacks of
anterior uveitis (AU) in patients with ankylosing spondylitis (AS). Methods. Consecutive …

Muscle wasting in male TNF-α blocker naïve ankylosing spondylitis patients: a comparison of gender differences in body composition

S Ibáñez Vodnizza, IM Visman, C van Denderen… - …, 2017 - academic.oup.com
Objective To assess gender differences in body composition (BC) in a cohort of AS patients
naïve to TNF-α blockers. Methods Patients included fulfilled the Modified New York criteria …

Fat mass lowers the response to tumor necrosis factor-α blockers in patients with ankylosing spondylitis

SEI Vodnizza, MT Nurmohamed, IM Visman… - The Journal of …, 2017 - jrheum.org
Objective. Our main objective was to assess the relationship between body composition (BC)
and response to tumor necrosis factor-α (TNF-α) blocker treatment in patients with …

[PDF][PDF] C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitis

…, MA Van der Weijden, IM Visman… - Clin Exp …, 2015 - clinexprheumatol.org
Objective C-reactive protein (CRP) levels are frequently used to determine disease activity
in patients with ankylosing spondylitis (AS), but these levels may not reflect disease activity. …

Changes in Tumor Necrosis Factor Inhibitor Drug Survival in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Over 15 Years

IM Visman, S Atiqi, M Boers, JWR Twisk… - The Journal of …, 2024 - jrheum.org
Objective To study changes in retention of first biologic disease-modifying antirheumatic
drug (DMARD) therapy over a period of 15 years in an inception cohort of patients with …

Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years

IM Visman, M Boers, D Vedder, JWR Twisk… - Annals of the …, 2022 - ard.bmj.com
3 Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination
in patients with autoimmune diseases in the Netherlands: a substudy of data from two …

[PDF][PDF] Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate

…, CLM Krieckaert, IM Visman… - Clin Exp …, 2017 - clinexprheumatol.org
Objective To observe long-term clinical response and drug survival in a prospective two-year
cohort study in rheumatoid arthritis (RA) patients starting adalimumab or etanercept …

Effect of the application of trial inclusion criteria on the efficacy of adalimumab therapy in a rheumatoid arthritis cohort

IM Visman, GM Bartelds, W Ouwerkerk… - The Journal of …, 2011 - jrheum.org
Objective. To evaluate the influence of inclusion criteria used in rheumatoid arthritis (RA)
trials with adalimumab on clinical outcome and response. Methods. The different inclusion …

[CITATION][C] Adalimumab Significantly Reduces the Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis

…, IM Visman… - JOURNAL OF …, 2014 - … PUBL CO 365 BLOOR ST E, STE …

[CITATION][C] Tapering of adalimumab based on therapeutic drug monitoring in rheumatoid arthritis

…, J Ruwaard, IM Visman… - ARTHRITIS & …, 2016 - … ST, HOBOKEN 07030-5774, NJ USA